Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
OpenAI Revenue Rises 18% in Q2 as Losses Widen and Anthropic Surges Ahead 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Alibaba Shares Fall as AI Spending Hits Profit 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Hyundai Motor Union Launches First Full Strike in Decade Over Wages, AI Job Risks 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
TikTok, DOJ Reach $400 Million Children’s Privacy Settlement 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
Add as a preferred source on Google
CAMBRIDGE, Mass., May 07, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin® and other proprietary platforms, today announced that it will host a conference call and webcast on Monday, May 14, 2018, at 5:00 p.m. ET to report financial results for the first quarter 2018 and provide business updates.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 7589367. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
[email protected]
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
[email protected]
212-362-1200
